Plain-English translation of NCT06300177 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it works better than standard chemotherapy (docetaxel) for people with advanced lung cancer that has a specific genetic mutation called KRAS G12C. The study will measure how long the cancer stays under control with each treatment. About 522 people will participate in this comparison.
Many people with this type of lung cancer stop responding to standard treatments over time. Researchers are testing whether this new medication might offer a better option for patients whose cancer has already progressed despite previous therapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new D-1553 pill or standard docetaxel chemotherapy. Treatment is given in 21-day cycles, and your cancer will be monitored with imaging scans to see how well the treatment is working. You will need to visit the study center regularly for check-ups, blood tests, and scans to track your progress and any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China